Navigation Links
BrainStorm Announces Financial Results for 2016 and Provides Business Update
Date:3/29/2017

HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 30, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the year ended December 31, 2016.

"2016 was a highly successful and pivotal year for Brainstorm, with a number of important achievements and significant progress made on clinical, regulatory and operational fronts," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm Cell Therapeutics.  "We announced positive top-line Phase 2 data of NurOwn® in the treatment of amyotrophic lateral sclerosis (ALS), demonstrating the potential of this therapy to halt or reverse ALS disease progression. Following our End of Phase 2 meeting with the FDA, we are making final preparations to begin a Phase 3 clinical trial, which when successful will position us to bring to ALS patients and their families a much needed and innovative ALS disease modifying therapy."

2016 and Recent Clinical Highlights:

  • Announced in July positive topline results from the U.S. Phase 2 randomized, placebo controlled study of NurOwn in patients with ALS.
  • Study achieved its primary objective, demonstrating that NurOwn was safe and well tolerated.
  • NurOwn also achieved multiple efficacy endpoints, showing clear evidence of a clinically meaningful benefit.
  • Response rates (based on ALSFRS-R responder analysis of halt or reverse of disease progression) were higher in NurOwn-treated subjects compared to placebo at all time points in the study out to 24 weeks.
  • In depth analysis of the Phase 2 data presented by Dr. James Berry of Mass. General Hospital at the 27th International Symposium on ALS/MND in Dublin, Ireland, demonstrating evidence that NurOwn has the potential to halt or reverse disease progression.
  • Completed a successful End-of-Phase 2 Meeting with the United States Food and Drug Administration (FDA).
  • Reached a general agreement with the FDA to proceed to a Phase 3 trial. Importantly, the FDA has accepted the key elements of the Phase 3 program to support a Biologic License Application (BLA) for NurOwn.
  • The planned Phase 3 clinical trial will be a randomized, double-blind, placebo-controlled multi-dose trial to be conducted at multiple sites in the U.S. and in Israel.
  • The trial is expected to begin enrolling patients in the second quarter of 2017.
  • Announced plans to contract with City of Hope's Center for Biomedicine and Genetics to produce clinical supplies of NurOwn adult stem cells for the company's planned Phase 3 clinical study in ALS.
  • City of Hope is expected to manufacture and provide NurOwn to all U.S. medical centers that will be participating in the Phase 3 trial.
  • Signed a Memorandum of Understanding (MOU) with the Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center (Ichilov Hospital) to explore the possibility of making NurOwn available to ALS patients under the provisions of Hospital Exemption regulation. 
  • The MOU also covers the participation of Tel Aviv Sourasky Medical Center in the planned Phase 3 trial that will investigate NurOwn in ALS.
  • The agreement is expected to be formalized in the first half of 2017.
  • Validated cryopreservation process for NurOwn in preparation for the planned Phase 3 clinical study in ALS. 
  • Cryopreservation will allow the Company to provide in Phase 3 repeated doses of autologous NurOwn from a single bone marrow aspirate.  This will avoid the need for patients to undergo repeated bone marrow aspirations.
  • 2016 and Recent Corporate Highlights:

  • Appointed Ralph Z. Kern, MD, MHSc to the positions of Chief Operating Officer and Chief Medical Officer.
  • Dr. Kern joined BrainStorm from Biogen, where he was Senior VP and Head of Worldwide Medical.  Previous industry appointments include Head of Neuroscience Medical Unit at Novartis and Global Medical Director of Personalized Genetic Health at Genzyme Corp.
  • Appointed June S. Almenoff, M.D., Ph.D., FACP, and Arturo O. Araya, M.A., M.B.A. to the Board of Directors.
  • Awarded a non-dilutive grant of approximately $1,470,000 from Israel's Office of the Chief Scientist (OCS).
  • Granted United States Patent No. 9,474,787 titled "Mesenchymal Stem Cells for the Treatment of CNS Diseases."
  • Financial Results for the Fourth Quarter Ended December 31, 2016
    Net R&D expenses for the fourth quarter of 2016 were $323,000, compared with $826,000 for the fourth quarter of 2015.  The decrease was primarily the result of decreased U.S. clinical trial expenses. In the fourth quarter of 2016, general and administrative expenses were $327,000, compared with $571,000 in the same period of 2015.  This was driven by decreased consultants expenses and decrease in Delaware Franchise Tax.  Net loss for the fourth quarter was $624,000 or ($0.03) per share, versus $1.4 million or ($0.07) per share in the same period of 2015.

    Financial Results for the Year Ended December 31, 2016 
    Research and Development expenses for the year ended December 31, 2016 were $2.3 million, compared to $4.9 million in the same period of 2015, primarily as a result of decreased U.S. clinical trial costs and partially offset by in the costs of activities related to the Israeli clinical trials and costs of materials. General and administrative expenses for the year were $2.8 million, compared to $3.6 million in the same period of 2015, primarily due to a decrease in the cost of our investor relations and public relations activities, our Delaware Franchise tax and rent. This decrease was partially offset by an increase in payroll expenses and consultants. Net loss for the year ended December 31, 2016, was $5.0 million, or ($0.27) per share, compared with a net loss of $8.5 million, or ($0.46) per share, for the year ended December 31, 2015. 

    As of December 31, 2016, BrainStorm had approximately $10.0 million in cash, cash equivalents and short-term deposits, compared with approximately $16.0 million at December 31, 2015. 

    About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo.  For more information, visit the company's website at www.brainstorm-cell.com.

    Safe-Harbor Statement
    Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

    CONTACTSMedia:
    Uri Yablonka
    Brainstorm Cell Therapeutics Inc.
    Phone: (646) 666-3188
    uri@brainstorm-cell.com

    Investors:
    Michael Rice
    LifeSci Advisors, LLC
    Phone: 646-597-6979
    mrice@lifesciadvisors.com

    BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETSU.S. dollars in thousands (Except share data)December 31,2 0 1 62 0 1 5U.S. $ in thousands ASSETSCurrent Assets:Cash and cash equivalents

    $           547$          428Short-term deposit

    9,44315,527Account receivable (Note 4)

    306759Prepaid expenses and other current assets

    14874Total current assets10,44416,788Long-Term Assets:Prepaid expenses and other long-term assets

    2521Property and Equipment, Net (Note 5)

    297271Total Long-Term Assets322292Total assets$      10,766$      17,080LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities:Accounts payables

    $         345$         1,169Accrued expenses

    1521,500Other accounts payable

    367283Total current liabilities 8642,952Total liabilities$     864$    2,952Stockholders' Equity:Stock capital:

    1111Common stock of $0.00005 par value - Authorized: 100,000,000 shares 
         at December 31, 2016 and December 31, 2015 respectively; Issued and outstanding: 
    18,687,987 and 18,643,288 shares at December 31, 2016 and 
         December 31, 2015 respectively.Additional paid-in-capital

    85,01484,258Accumulated deficit

    (75,123)(70,141)Total stockholders' equity9,90214,128Total liabilities and stockholders' equity$         10,766$          17,080

    BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONSU.S. dollars in thousands (Except share data)Year endedDecember 31,2 0 1 62 0 1 5U.S. $ in thousandsOperating expenses:Research and development, net

    $       2,250$       4,949General and administrative

    2,8333,587Operating loss(5,083)(8,536)Financial expenses (income), net

    (101)(48)Taxes on income (Note 10)

    --Net loss$     (4,982)$     (8,488)Basic and diluted net loss per share from continuing operations                                                                              

    $       (0.27)$       (0.46)Weighted average number of shares outstanding used in computing basic and diluted net loss per share

    18,663,16218,405,610

    To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-announces-financial-results-for-2016-and-provides-business-update-300431578.html


    '/>"/>
    SOURCE BrainStorm Cell Therapeutics Inc.
    Copyright©2017 PR Newswire.
    All rights reserved


    Related biology technology :

    1. BrainStorm Cell Therapeutics to Report Third Quarter 2014 Financial Results on Thursday, November 13
    2. BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israels Chief Scientist Office
    3. BrainStorm Cell Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14
    4. BrainStorm Cell Therapeutics to Report Second Quarter 2015 Financial Results on Thursday, August 13
    5. BrainStorm Cell Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
    6. BrainStorm Cell Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa
    7. BrainStorm Cell Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update
    8. BrainStorm Awarded Additional $735,000 Non-Dilutive Grant for 2015 from Israels Office of the Chief Scientist
    9. BrainStorm Hosting Conference Call to Update Shareholders on Important Developments
    10. BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
    11. BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/4/2019)... , ... September 03, 2019 ... ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene ... Science & Technology will present at the upcoming Nordic Life Science Days ...
    (Date:8/27/2019)... ... 27, 2019 , ... Dr. Kim Carlson is a veterinary surgeon practicing in ... Surgical Group , a new surgical practice in San Mateo. She is currently ... more veterinary specialists as the practice grows. , When asked about the opening of ...
    (Date:8/15/2019)... (PRWEB) , ... August 15, 2019 , ... ... Scientific Advisory Board. Mr. Lawrence is a member of the Institute of Food ... Safety and Health (IFSH) Advisory Board, Joint Institute for Food Safety and Applied ...
    (Date:8/6/2019)... ... August 06, 2019 , ... The San Diego Biotechnology ... the biweekly SDBN BUZZ podcast focused on connecting the region’s biotech community and ... to promote the region and attract external employers, investors, scientists, and others who ...
    Breaking Biology Technology:
    (Date:8/29/2019)... ... , ... Lajollacooks4u has expanded its team as it gears up for a ... seen record growth in 2019, having hosted a multitude of team-building events and cooking ... visited the company’s La Jolla-based venue, and Lajollacooks4u has worked hard to accommodate the ...
    (Date:8/27/2019)... Fla. (PRWEB) , ... August 27, 2019 , ... ... in life science and drug development. This episode is scheduled to broadcast 4Q/2019. ... explore Debiopharm, a biopharmaceutical research, development, investment and manufacturing company. The show will ...
    (Date:8/21/2019)... ... August 20, 2019 , ... Cutting Edge ... for the spine, today announced the 510(K) clearance of its novel SI joint ... is proven to improve osseointegration through superior hydrophilicity and optimized surface chemistry, as ...
    Breaking Biology News(10 mins):